Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Many types of cancers overexpress a receptor for the vitamin folate (Folate Receptor). This
Phase 2 study will utilize a standard imaging radionuclide, technetium-99m, conjugated to a
ligand (EC20) designed to bind to the folate receptor. The study is designed as an
open-label, baseline-controlled study.